VolitionRx Limited (NYSE American: VNRX) has announced a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. This agreement supports Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies, leveraging their disease expertise, regulatory capabilities, and installed analyzer base to accelerate development and commercialization.
The collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. Volition believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring, and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
For more details, the full press release can be found at https://ibn.fm/TSMG4. Further information about Volition is available on their website at https://volition.com/.
